PSK Pharma (part of Rus Biopharm Group) is a fully integrated bio-pharmaceutical company. The manufacturing units are located in Dubna.
In small molecules business, company has dedicated facility for manufacturing most of its Active Pharmaceutical Ingredients. These APIs are further used to make formulations in seven different forms of formulations.
In biotech, company has one of the best product portfolio in the country, with 5 biotech products already in the market and 7 more at various stages of registration. The company has a state of art formulation unit, and a Drug Substance unit will be ready by June of 2023, making it fully integrated biotech manufacturer.
PSK Pharma is undisputed leader in Asthma and COPD segment in Russia, having 17 inhalation products in its portfolio. The company has launched 12 «first generics» in Russia and would continue to launch the first generics in Russia for the products that are termed as «complex generics». Apart from inhalation segment, PSK Pharma manufacturers products for treatment of Oncology, Auto-immune disorders, HIV, TB, GI and CNS.
Since 2017, PSK Pharma has invested 4 Billion Rubles in its development. Another 6 Billion Rubles would be invested in expansion from 2023 till end 2025.
GENERIUM is a full-cycle innovative high-end pharmaceutical company. We are the leader in Russian orphan pharmaceutical market.
GENERIUM possesses its own R&D park, which is capable to handle the full cycle of development of any biological drug, from molecule design to commercial production. We are collaborating in science with leading biotechnological companies and institutes from all over the world.
GENERIUMs manufacturing facilities are equipped with high-end equipment. The work is organized under GMP standards and our plants are ready to produce any kind of biological drugs or ATMPs.
Our mission – our ideas to save life and health.
BIOCAD is one of the largest innovative biotech companies in Russia. It brought together world-class R&D centers, modern pharmaceutical and biotechnological production, and preclinical and clinical trials, compliant with international standards.
BIOCAD is a full-cycle drug development company, from molecule search to mass production and patient support. The drugs are intended for the treatment of oncological, autoimmune and other socially significant diseases. Present product portfolio includes 62 medical products, 9 of them are original, 22 - biological. Over 40 products are now in different development stages.
There are more then 3000 people working in BIOCAD, 1/3 of them are researchers and scientists. International offices of the company are located in Brazil, China, Vietnam, India and UAE.
JSC "Pharmasyntez-Nord" was founded in 2010. It is one of the largest pharmaceutical manufacturers of socially significant medicines in Russia and is located in Saint Petersburg on the territory of the special economic zone "Novoorlovskaya". It is part of the Pharmasyntez Group founded in 1997.
The plant specializes in the development and production of antitumor drugs, biologicals based on monoclonal antibodies, and drugs for treatment of autoimmune diseases.
The investment project for the construction of the research and production complex of "Pharmasyntez-Nord" involves three stages, two of which have already been put into commercial operation.
The amount of investment in this project is estimated at about 14 billion rubles, of which over 5 billion rubles have already been implemented.
The company's product portfolio currently includes 45 medicines, 99% of which are included in the List of Vital and Essential Drugs of the Ministry of Health of Russia.
The project is aimed at import substitution and ensuring secure provision of medicines in the Russian Federation .